摘要 |
The invention concerns prenatal screening of chromosomal aberrations, more particularly, through identification of novel markers of chromosomal aberrations, in particular, trisomy 21, whereof the assay based on a body fluid of the pregnant woman enables, alone or in combination with other assays, the probability that the fetus suffers from a chromosomal aberration to be more accurately determined than that by currently used tests.
|